ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
5 files

Studies on Computational Molecular Interaction Between SARS-CoV-2 Main Protease and Natural Products

preprint
revised on 30.03.2020, 15:38 and posted on 31.03.2020, 09:24 by Manish Manish
A combination of docking approaches, scoring functions, molecular dynamic simulation, and literature mining have been employed to screen readily available natural products (unique 27256 chemical entities, 598435 unique compounds), which can inhibit the SARS-CoV-2 main protease. Theaflavin digallate, a major constituent of black tea, has been observed to be as three top hits after the virtual screening of 598435 unique compounds. The main protease-theaflavin digallate complex appeared to be in the metastable stage and interact with critical active site residues of the main protease during molecular dynamics simulation for 200 ns. Invitro evidence on main protease inhibition of 2003 SARS-CoV by theaflavin digallate is available in the scientific literature. As evident by the dynamics of intermolecular interactions, theaflavin digallate, forms approximately three hydrogen bonds with Glu166 of main protease, mostly through hydroxyl groups in the benzene ring of benzo(7) annulen-6-one. Glu166 is the most critical amino acid for main protease dimerization, which in turn, is necessary for catalytic activity. We have employed chloroquine and epigallocatechin gallate (green tea component) as a control set. Based on computational molecular interaction and data available in scientific literature, theaflavin digallate can inhibit the main protease of SARS-CoV-2.

Funding

CSIR-Pool Scientist Scheme

SERB/YSS/2015/00031

History

Email Address of Submitting Author

manish81_sbt@jnu.ac.in

Institution

Jawaharlal Nehru University

Country

India

ORCID For Submitting Author

0000-0002-3964-4044

Declaration of Conflict of Interest

None

Version Notes

This is the second version of manuscript.

Exports

Logo branding

Exports